A physician-author's blog analysing biotech and oncology developments, including clinical trial data, drug mechanisms and the implications of AI for medicine. Posts include conflict-of-interest disclosures and give detailed scientific commentary on specific companies and drugs.

Long-form essays on biology, drug discovery and machine learning, currently a three-part series on whether organoids have delivered on their promise. The author, who works on health data philanthropy, offers skeptical, opinionated analysis of the scientific literature with occasional life and job updates.

A market intelligence newsletter tracking life sciences real estate deals across Europe, combining weekly deal roundups with data-driven analysis from its own deals database. Readers get headline deals for free, with the full list of deals reserved for paying members.

Independent investment research newsletter covering alternative energy, longevity, biotech and emerging markets, with issues structured as problem, solution, opportunity and investment thesis. Readers get data-heavy analyses of specific companies and sectors, including catalysts, financial position and risks.